Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709655 · ClinicalTrials.gov registry record · Phase 3
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 683
- Enrollment target
NCT02709655 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 683 participants.
The verdict
NCT02709655, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 683 participants
- Enrollment target
Study Summary
Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).
Interventions
- OTHER Placebo
- DRUG Vortioxetine 10 mg/day
- DRUG Vortioxetine 20 mg/day
- DRUG Fluoxetine 20mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 683 participants |
| Start Date | 2016-05-18 |
| Est. Completion | 2022-01-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709655
The ClinicalTrials.gov registry entry for NCT02709655 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 683 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02709655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02709655 about?
NCT02709655 is a clinical study titled "Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)". Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).
What is the current status of trial NCT02709655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 683 participants. The study started on 2016-05-18. Estimated completion is 2022-01-21.
What interventions are being tested in trial NCT02709655?
The interventions under investigation include: Placebo (OTHER), Vortioxetine 10 mg/day (DRUG), Vortioxetine 20 mg/day (DRUG), Fluoxetine 20mg/day (DRUG).
Who is sponsoring clinical trial NCT02709655?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.